European Committee Says Alzheimer's Treatment Leqembi shouldn't Get Marketing Approval

AP24208465310572
Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval.

New contents